Preeclampsia diagnostics includes tests to detect the condition in pregnant women. It involves measuring blood pressure and testing urine samples for protein. As the disease progresses, additional tests are done to check kidney and liver function, and blood platelet count. Ultrasound imaging of vital organs is also carried out. Early diagnosis is crucial to effectively manage preeclampsia and prevent life-threatening complications in both mother and baby.
The Preeclampsia Diagnostics market is estimated to be valued at US$ 1,587.53 Mn or Mn in 2023 and is expected to exhibit a CAGR of 11.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the market is increasing research into novel diagnostic biomarkers. Researchers are investigating potential circulating biomarkers such as anti-angiogenic factors, placental growth factor (PIGF), and soluble fms-like tyrosine kinase-1 (sFlt-1) that can enable early detection of preeclampsia. Biomarker panels combining multiple markers show promise for improved predictive performance over individual markers. Growing adoption of imaging modalities such as magnetic resonance imaging (MRI) and Doppler ultrasonography for detailed placental examination is another key trend. These non-invasive methods provide valuable anatomical and hemodynamic data for better risk assessment and management of high-risk patients.
Threat of new entrants: The threat of new entrants into the preeclampsia diagnostics market is moderate. It requires huge investment and compliance with regulations set by regulatory bodies to enter this market.
Bargaining power of buyers: The bargaining power of buyers is moderate in this market. The availability of various diagnostic tests gives buyers options to choose from.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of a large number of suppliers. Suppliers do not have pricing power in this market.
Threat of new substitutes: The threat of new substitutes in the preeclampsia diagnostics market is low as there are limited alternative diagnostics available for preeclampsia currently.
Competitive rivalry: Competition in the preeclampsia diagnostics market is high due to presence of established as well as emerging players. Players compete based on diagnostic test offerings, pricing, and marketing strategies.
The Global Preeclampsia Diagnostics Market Size is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing adoption of advanced diagnostic tests.
Regional analysis: North America dominates the global preeclampsia diagnostics market owing to supportive government initiatives and healthcare reforms. Asia Pacific is expected to grow at the fastest pace during the forecast period.
Key players: Key players operating in the preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. Players are focusing on geographic expansion and new product launches.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it